Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Impact
        • Technologies
        • Commercialisation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research.

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in memory
        • Advise on our research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Careers
        • Study opportunities
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events.

        • News
        • Statements
        • Events
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges.

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > New genetic tool predicts risk of liver disease in heavy drinkers

New genetic tool predicts risk of liver disease in heavy drinkers

Date time 28 August, 2024
News Type News type Media release
Clinical Professor Devanshi Seth
An international research group led by the Centenary Institute has developed a new genetic risk prediction tool to identify heavy drinkers most at risk of developing alcohol-associated cirrhosis, a severe form of liver disease.

Reported in the journal Hepatology Communications, the tool offers new hope for the early detection and prevention of alcohol-associated cirrhosis, a condition responsible for over 300,000 global deaths annually.

While excessive alcohol consumption is known to cause liver damage, not all heavy drinkers develop cirrhosis, which is characterised by scarring of the liver. The newly developed tool, known as a polygenic risk score (PRS), helps pinpoint individuals most likely to suffer from alcohol-associated cirrhosis based on their genetic makeup.

In developing the PRS, the researchers compared the genetic profiles of thousands of patients with alcohol-associated cirrhosis to those of heavy drinkers without liver damage. Analysing millions of genetic variations, a risk score was derived from 20 specific genetic markers.

Clinical Professor Devanshi Seth, the senior author of the study and researcher at both the Centenary Institute’s Centre for Healthy Ageing and Drug Health Services, Sydney Local Health District, said the PRS was extremely effective.

“Our polygenic risk score is a powerful new approach to predicting alcohol-associated cirrhosis through an individual’s genes. It allows us to identify individuals at high risk, enabling earlier intervention and preventive measures to help stop liver disease before it progresses,” said Clinical Professor Seth.

The study also revealed that the PRS significantly improves the prediction of alcohol-associated cirrhosis when combined with other traditional (non-genetic) risk factors such as drinking habits, age, body mass index (BMI) and diabetes status. Further, the tool has been found to be useful in predicting the risk of other liver diseases related to metabolic (non-alcoholic) factors.

“Our tool not only predicts the risk of alcohol-associated cirrhosis but has also demonstrated its utility in identifying risks for other liver diseases such as fatty liver disease, suggesting that shared genetic factors are involved,” said Clinical Professor Seth.

“Moreover, individuals who learn that they are at higher risk through this tool may be motivated to adopt healthier lifestyles to help prevent the progression of disease,” she added. 

“This tool can aid in the early detection and prevention of multiple liver conditions, offering a far more comprehensive approach to liver health.”

The research was undertaken by the multi-national GenomALC Consortium led by Clinical Professor Seth and funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) a part of the National Institutes of Health (NIH), USA.

[ENDS]

Publication: A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry.

Themes

  • Healthy Ageing

    Healthy Ageing

People

  • Clinical Professor Devanshi Seth

    Faculty

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

New genetic tool predicts risk of liver disease in heavy drinkers

Download

Recent Stories

  • New grant targets longer-lasting islet cell treatments for type 1 diabetes

    Dr Lise Hunault, a researcher in the Centenary Institute’s Centre for Biomedical AI, has been awarded a major research grant from Breakthrough T1D, the leading global type 1 diabetes research and advocacy organisation, to advance islet-cell replacement therapies for type 1 diabetes.
    News Type: Research News
    Date 16 Mar 2026
  • Centenary marks International Women’s Day with inspiring speakers

    The Centenary Institute community came together to celebrate International Women’s Day 2026, with a special event highlighting this year’s Australian theme, ‘Balancing the Scales.’
    News Type: Community
    Date 11 Mar 2026
  • Vaxosome launched to develop next-generation mRNA vaccines

    A new biotechnology company, Vaxosome, has been launched to develop next-generation vaccines aimed at tackling some of the world’s most challenging infectious diseases.
    News Type: Research News
    Date 10 Mar 2026
  • Centenary partners in transformative national liver health program

    The Snow Medical Research Foundation has today announced major long-term funding of $15.5 million for a new national research program targeting fatty liver disease, a condition that affects up to one in three Australians. The Centenary Institute will play a key role in the collaborative effort.
    News Type: Research News
    Date 05 Mar 2026

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About us
  • Governance
  • Corporate information

Research

  • Our researchers
  • News

Careers & studies

  • Career opportunities
  • Student opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement
  • Staff Intranet

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram